百奥泰：乌司奴单抗注射液获欧洲EMA上市批准

Core Viewpoint - The company Baiotai's product, Usymro (Ustekinumab injection), has received marketing approval from the European Medicines Agency (EMA) for the treatment of moderate to severe plaque psoriasis (PsO), active psoriatic arthritis (PsA), and moderate to severe active Crohn's disease (CD) [1] Group 1 - The approval of Usymro will further expand the company's international market presence and enhance the product's global influence [1] - The product is already in the commercialization process in several regions, including the United States, Russia, Brazil, and the European Union [1] - This approval is expected to have a positive impact on the company's long-term operational performance [1]